Anonymous
Guest
Anonymous
Guest
hate to admit it, this is where biotech is heading following big pharma
BG-12 will be submitted in this first half of this year.
FF will have to expand by around 45; still competing with Novartis' larger sales force
BG-12 will have a dedicated FF in first position; it will not be Ty reps
Smaller footprints? not happening